Pyxis Oncology secured up to $114 million through a private placement led by BVF Partners to fund the development of its cancer drug MICVO. The financing will extend the company's cash runway into Q2 2027, supporting ongoing trials for head and neck squamous cell carcinoma. Updated Phase 1 monotherapy data is expected in Fall 2026, with combination therapy data due in Q4 2026. This funding strengthens Pyxis's ability to advance MICVO toward regulatory and clinical milestones, aiming to improve treatment for difficult cancers.
Hershey is preparing to announce its Q3 earnings on October 29, with analysts forecasting earnings per share (EPS) of $2.12, a 63% increase from last year, and revenue of $3.25 billion, up 2.3%. The company has shown strong recent performance, with Q...
3M reported strong Q3 2026 earnings with adjusted EPS of $2.50, beating estimates of $2.38, and GAAP profit rising to $1.37 billion from $834 million a year earlier. Sales reached $6.6 billion, slightly below estimates, but showed 3.3% organic growth...
Alaska Air Group is set to report Q3 2026 earnings with analysts expecting a 66.7% drop in earnings per share to $0.35, despite a 14.5% increase in revenue to $4.31 billion driven by strong travel demand. Passenger revenue is forecast to rise 10.2%, ...
Baba, an applied AI company focused on modernizing Medicare and Medicaid care, has raised $40 million in a Series A funding round led by FirstMark Capital, with participation from CVS Health Ventures and others. The funding will help Baba expand its ...
Richard Campbell-Breeden, a seasoned investment banker with 37 years of experience including 27 years at Goldman Sachs, has joined SEDA Experts LLC as Managing Director. His expertise in mergers and acquisitions, corporate finance, and governance wil...
